Reactivation of Hepatitis B Virus among Malignancy Patients Undergoing Chemotherapy: A Prospective Cohort Study

• DOI: 10.4103/jmms.jmms_17_24
• Publication Date: 2024-08-06T17:23:55Z
• Authors: Mohit Sethia; Rahul Jain; Vani Singh; Santosh Singh; Saurabh Mahajan; Harshul Jain; Jyoti Yadav; A. K. Yadav
• Keywords: Hepatitis B

Abstract Introduction: Reactivation of hepatitis B virus (HBV) can occur in patients receiving short-term chemotherapy, long-term immunosuppressive therapy, or disease-modifying antirheumatic agents for rheumatological diseases and is more common surface antigen-positive patients. However, there a lack data reactivation among malignant undergoing chemotherapy resolved HBV Methodology: A prospective cohort study 200 oncological on was conducted the year. Patients underwent thorough physical examination; baseline assessment biochemical test were repeated at each follow-up. Results: The majority females 40–60-year age group. Age serum albumin levels significantly different ( P < 0.05) reactivated versus nonreactivated groups. Hepatitis seen 14 (7%) with maximum rituximab therapy group (11.26%). There no statistically significant difference ALT between who experienced those did not. Conclusion: In present population, 7% had reactivation. identifies old age, low albumin, as risk factors Prophylactic antiviral seems to be effective has occurred this